nextpointtx.comHealthcare / BioTech & PharmaFounded: 2020Funding to Date: $163.11MM
NextPoint Therapeutics, Inc. is a clinical-stage biotechnology firm that is developing precision oncology therapeutics. NextPoint Therapeutics' commitment to pioneering new avenues in cancer treatment, aiming to create therapies that are more effective and less invasive, potentially offering new alternatives to patients with various types of cancer. Their approach is grounded in precision medicine, seeking to tailor treatments that can directly target cancer cells while minimizing harm to healthy tissues
Funding Date | Share Class | Amount Raised | Price per Share | Post-Money Valuation | Key Investors | |
---|---|---|---|---|---|---|
02/14/2024 | Series B | $122.48MM | $xx.xx | $268.64MM | MPM Capital, Bayer, Sanofi Ventures, Invus, Catalio Capital, Sixty Degree Capital, Binney Street Capital, Gordon Freeman, Arkin Bio-Capital, WTT Investment, PagodaTree Partners | |
Price per Share
$xx.xx
Shares Outstanding
20,413,230
Liquidation Pref Order
1
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
8.0%
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
N/A
Key Investors
MPM Capital, Bayer, Sanofi Ventures, Invus, Catalio Capital, Sixty Degree Capital, Binney Street Capital, Gordon Freeman, Arkin Bio-Capital, WTT Investment, PagodaTree Partners
|
||||||
08/31/2020 | Series A-2 | $22.7MM | $xx.xx | $127.44MM | MPM Capital, Binney Street Capital, Gordon Freeman | |
Price per Share
$xx.xx
Shares Outstanding
3,783,440
Liquidation Pref Order
1
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
8.0%
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
N/A
Key Investors
MPM Capital, Binney Street Capital, Gordon Freeman
|
||||||
08/31/2020 | Series A | $15.53MM | $xx.xx | $127.44MM | MPM Capital, Binney Street Capital, Gordon Freeman | |
Price per Share
$xx.xx
Shares Outstanding
4,436,175
Liquidation Pref Order
1
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
8.0%
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
N/A
Key Investors
MPM Capital, Binney Street Capital, Gordon Freeman
|
||||||
12/31/2018 | Series Seed | $2.4MM | $xx.xx | $8MM | Undisclosed Investors | |
Price per Share
$xx.xx
Shares Outstanding
2,400,000
Liquidation Pref Order
2
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
8.0%
Cumulative
Non-cumulative
Participating
Participating
Participation Cap
1000.0
Key Investors
Undisclosed Investors
|